Why the study?
Does nebivolol prevent doxorubicin-induced cardiotoxicity in breast cancer patients?
Does nebivolol prevent doxorubicin-induced cardiotoxicity in breast cancer patients?
Nebivolol may prevent short-term anthracycline-induced cardiomyopathy in breast cancer patients, with early dysfunction effectively screened using advanced echocardiographic imaging (TDI and STI).
May support short-term nebivolol use in anthracycline-treated patients; leaves open confirmation by randomized trials before practice change.
The results of this study show the benefit of new echocardiographic imaging methods such as TDI and STI in the screening of early cardiac dysfunction induced by cytostatic treatment. Nebivolol treatment prevented the occurrence of anthracyclines-induced cardiomyopathy in the short term. In order to confirm these preliminary results, larger studies with a longer follow-up period are required.
No takes yet. Share an insight, caveat, or question.
Cochera et al. (2018) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: